{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:37:31Z","timestamp":1780630651809,"version":"3.54.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/aci.0b013e32835571f6","type":"journal-article","created":{"date-parts":[[2012,6,22]],"date-time":"2012-06-22T16:56:17Z","timestamp":1340384177000},"page":"412-420","source":"Crossref","is-referenced-by-count":20,"title":["Calcineurin inhibitors in chronic urticaria"],"prefix":"10.1097","volume":"12","author":[{"given":"Timothy D.","family":"Trojan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210128","first-page":"214","article-title":"Epidemiology of urticaria in Spain.","volume":"14","author":"Gaig","year":"2004","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R2-13-20210128","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2230.2010.03840.x","article-title":"Epidemiology of urticaria: a representative cross-sectional population survey.","volume":"35","author":"Zuberbier","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"R3-13-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report.","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"R4-13-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.anai.2011.06.008","article-title":"Utility of routine laboratory testing in management of chronic urticariaangioedema.","volume":"107","author":"Tarbox","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R5-13-20210128","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2009.11.047","article-title":"The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria.","volume":"125","author":"Staevska","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"R6-13-20210128","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2133.1998.02175.x","article-title":"The characteristics of urticaria in 390 patients.","volume":"138","author":"Humphreys","year":"1998","journal-title":"Br J Dermatol"},{"key":"R7-13-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-3083.2011.04185.x","article-title":"Pharmacological rationale for the treatment of chronic urticaria with second-generation nonsedating antihistamines at higher-than-standard doses.","volume":"26","author":"Zuberbier","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R8-13-20210128","first-page":"361","article-title":"Second-generation H1-antihistamines in chronic urticaria: an evidence-based review.","volume":"12","author":"Kavosh","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"R9-13-20210128","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jaci.2009.01.065","article-title":"Low-dose cyclosporine is a good option for severe chronic urticaria.","volume":"123","author":"Kessel","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"R10-13-20210128","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1398-9995.2009.02178.x","article-title":"EAACIGA2LENEDFWAO guideline: management of urticaria.","volume":"64","author":"Zuberbier","year":"2009","journal-title":"Allergy"},{"key":"R11-13-20210128","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1365-2222.2004.02019.x","article-title":"Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study.","volume":"34","author":"Nettis","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"R12-13-20210128","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaci.2003.10.002","article-title":"The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results.","volume":"113","author":"Bagenstose","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R13-13-20210128","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1067\/mai.2002.123236","article-title":"TH1TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction.","volume":"109","author":"Ying","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"R14-13-20210128","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJM199306033282204","article-title":"Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria.","volume":"328","author":"Hide","year":"1993","journal-title":"N Engl J Med"},{"key":"R15-13-20210128","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.coi.2008.09.005","article-title":"New concepts in chronic urticaria.","volume":"20","author":"Vonakis","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"R16-13-20210128","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1111\/j.1440-0960.2010.00658.x","article-title":"Detection of CD4CD25FOXP3 regulatory T cells in peripheral blood of patients with chronic autoimmune urticaria.","volume":"52","author":"Sun","year":"2011","journal-title":"Australas J Dermatol"},{"key":"R17-13-20210128","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0091-6749(96)70163-X","article-title":"Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells.","volume":"98","author":"Sperr","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"R18-13-20210128","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1523-1747.ep12614216","article-title":"Anti-inflammatory effect of FK-506 on human skin mast cells.","volume":"99","author":"de Paulis","year":"1992","journal-title":"J Invest Derma"},{"key":"R19-13-20210128","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.4049\/jimmunol.151.10.5563","article-title":"In vivo characterization of the anti-inflammatory effect of cyclosporin A on human basophils.","volume":"151","author":"Casolaro","year":"1993","journal-title":"J Immunol"},{"key":"R20-13-20210128","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.4049\/jimmunol.144.10.3891","article-title":"Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin.","volume":"144","author":"Cirillo","year":"1990","journal-title":"J Immunol"},{"key":"R21-13-20210128","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-2222.2005.02242.x","article-title":"Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria.","volume":"35","author":"Marsland","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"R22-13-20210128","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2133.2000.03664.x","article-title":"Randomized double-blind study of cyclosporin in chronic idiopathic urticaria.","volume":"143","author":"Grattan","year":"2000","journal-title":"Br J Dermatol"},{"key":"R23-13-20210128","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/j.1398-9995.2009.02054.x","article-title":"Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis.","volume":"64","author":"Brandt","year":"2009","journal-title":"Allergy"},{"key":"R24-13-20210128","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaad.2006.04.078","article-title":"Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.","volume":"55","author":"Vena","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R25-13-20210128","first-page":"164","article-title":"Comparison of short- and long-term cyclosporine A therapy in chronic idiopathic urticaria.","volume":"15","author":"Baskan","year":"2004","journal-title":"J Dermatolog Treat"},{"key":"R26-13-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1081\/IPH-100103860","article-title":"Cyclosporin A in patients affected by chronic idiopathic urticaria: a therapeutic alternative.","volume":"23","author":"Loria","year":"2001","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"R27-13-20210128","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1346-8138.2008.00466.x","article-title":"Low-dose and short-term cyclosporine treatment in patients with chronic idiopathic urticaria: a clinical and immunological evaluation.","volume":"35","author":"Serhat Inaloz","year":"2008","journal-title":"J Dermatol"},{"key":"R28-13-20210128","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1398-9995.1997.tb00996.x","article-title":"Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria.","volume":"52","author":"Toubi","year":"1997","journal-title":"Allergy"},{"key":"R29-13-20210128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2340\/00015555-0939","article-title":"Treatment of autoimmune urticaria with low-dose cyclosporin A: a one-year follow-up.","volume":"91","author":"Boubouka","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"R30-13-20210128","first-page":"285","article-title":"Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation.","volume":"24","author":"Di Gioacchino","year":"2003","journal-title":"Allergy Asthma Proc"},{"key":"R31-13-20210128","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-4632.2010.04384.x","article-title":"Response to oral cyclosporine therapy and high sensitivity-CRP level in chronic idiopathic urticaria.","volume":"49","author":"Ohtsuka","year":"2010","journal-title":"Int J Dermatol"},{"key":"R32-13-20210128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1468-3083.1999.tb00815.x","article-title":"Short-term oral cyclosporine for chronic idiopathic urticaria.","volume":"12","author":"Ilter","year":"1999","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Pt 1","key":"R33-13-20210128","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/0190-9622(91)70308-O","article-title":"Oral cyclosporine for severe chronic idiopathic urticaria and angioedema.","volume":"25","author":"Fradin","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"R35-13-20210128","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1398-9995.2010.02419.x","article-title":"Cyclosporine-A in severe chronic urticaria: the option for long-term therapy.","volume":"65","author":"Kessel","year":"2010","journal-title":"Allergy"},{"key":"R36-13-20210128","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/039463201102400123","article-title":"Cyclosporin-A efficacy in chronic idiopathic urticaria.","volume":"24","author":"Di Leo","year":"2011","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R37-13-20210128","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1525-1470.2009.00869.x","article-title":"Experience with cyclosporine in children with chronic idiopathic urticaria.","volume":"26","author":"Doshi","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"R38-13-20210128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1747.2003.12040.x","article-title":"Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.","volume":"120","author":"Paul","year":"2003","journal-title":"J Investig Dermatol"},{"key":"R39-13-20210128","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaad.2010.04.046","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan.","volume":"65","author":"Chen","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R40-13-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2340\/00015555-0360","article-title":"Long-term follow-up of cancer risk in patients treated with short-term cyclosporine.","volume":"88","author":"Vakeva","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"R41-13-20210128","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/1529-0131(199811)41:11<1930::AID-ART6>3.0.CO;2-N","article-title":"No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis.","volume":"41","author":"van den Borne","year":"1998","journal-title":"Arthritis Rheum"},{"key":"R43-13-20210128","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2133.1994.tb02935.x","article-title":"Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis.","volume":"130","author":"Laburte","year":"1994","journal-title":"Br J Dermatol"},{"key":"R44-13-20210128","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2133.1999.02977.x","article-title":"Intermittent short courses of cyclosporin (Neoral) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.","volume":"141","author":"Ho","year":"1999","journal-title":"Br J Dermatol"},{"key":"R45-13-20210128","first-page":"150","article-title":"Renal structure and function effects after low dose cyclosporine in psoriasis patients: a preliminary report.","volume":"43","author":"Messana","year":"1995","journal-title":"Clin Nephrol"},{"key":"R46-13-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-3083.2011.03992.x","article-title":"Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in nonplaque psoriasis.","volume":"25","author":"Maza","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R47-13-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1529-8019.2007.00137.x","article-title":"Systemic ciclosporin and tacrolimus in dermatology.","volume":"20","author":"Madan","year":"2007","journal-title":"Dermatol Ther"},{"key":"R48-13-20210128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaad.2004.09.023","article-title":"Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study.","volume":"52","author":"Kessel","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R49-13-20210128","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaad.2009.05.017","article-title":"Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference.","volume":"62","author":"Rosmarin","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R50-13-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/archdermatol.2007.5","article-title":"Annual direct and indirect healthcare costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients.","volume":"144","author":"DeLong","year":"2008","journal-title":"Arch Dermatol"}],"container-title":["Current Opinion in Allergy &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0b013e32835571f6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T20:57:57Z","timestamp":1687553877000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130832-201208000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/aci.0b013e32835571f6","relation":{},"ISSN":["1528-4050"],"issn-type":[{"value":"1528-4050","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}